Download Image
    
Share
  
Post
c19early.org
Ensovibep for COVID-19
2 studies with >800 patients
Serious outcome risk
Ensovibep
Control
Significantly lower risk for hospitalization.
One study shows significant benefit.
COVID-19 Ensovibep studies · October 2026
Ensovibep requires IV infusion, but may be less variant dependent than monoclonal antibodies.
Covid Analysis Ensovibep for COVID-19: real-time meta-analysis of 2 studies (Version 9)
Significantly lower risk is seen for hospitalization. One study shows significant benefit. Meta-analysis using the most serious outcome reported shows 47% [-108‑87%] lower risk, without reaching statistical significance. Early ..
Feb 6
2025
 Mourad et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2025.02.002 Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial
28% lower mortality (p=0.16) and 11% lower combined mortality/hospitalization (p=0.47). Analysis of 2,311 hospitalized COVID-19 patients from four randomized controlled trials (ACTIV-3/TICO) showing no significant difference in long-term mortality with sotrovimab, amubarvimab/romlusevimab, tixagevimab-cilgavimab, or ensovibep.
May 3
2024
 Kingsley et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofae233 The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study
89% lower mortality (p=0.06), 78% fewer combined hospitalization/ER visits (p=0.02), 87% lower hospitalization (p=0.01), and 87% improvement (p=0.01). RCT 407 mild to moderate COVID-19 outpatients showing faster viral clearance, lower risk of hospitalization/ER visits, and shorter time to sustained recovery with ensovibep treatment (75/225/600mg single infusion). There were 2 COVID-19 r..
Aug 9
2022
 Barkauskas et al., Annals of Internal Medicine, doi:10.7326/M22-1503 Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
28% lower mortality (p=0.16), 11% lower combined mortality/hospitalization (p=0.47), 6% improved recovery (p=0.55), and 7% higher hospital discharge (p=0.46). RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg. Long-term results are reported in [Mourad]
Nov 16
2021
 Molecular Partners, Press Release Molecular partners provides update from ACTIVE-3 global clinical study of ensovibep in patients hospitalized with COVID-19
News release reporting that ensovibep was terminated for futility in ACTIV-3. 470 patients had been randomized.
Feb 3
2021
 Rothenberger et al., bioRxiv, doi:10.1101/2021.02.03.429164 Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants
In silico, in vitro, and hamster study of ensovibep, a DARPin candidate that can engage all three units of the spike protein trimer to inhibit ACE2 interaction, showing efficacy for common variants, and efficacy comparable to casirivimab/..